For the Inventor, By the Inventor

Enter inventor name

Maurizio Botta

USPTO Granted Patents = 13 (Patent Applications = 5)

CIPO Patents = 2 (Patent Applications = 2)

EPO Patents = 8 (Patent Applications = 12)

Average Co-Inventor Count = 6.0

ph-index = 1

Forward Citations = 16(Granted Patents)

Location History:

Siena, IT (2008 - 2021)
Castelnuovo Berardenga, IT (2011 - 2023)

Company Filing History:

Universitá Degli Studi Di Siena

Azienda Ospedaliera Universitaria Senese

Università Degli Studi Di Roma "La Sapienza"

Cygnet Biosciences B.v.

5. 1 out of 343

Sigma-tau Industrie Farmaceutiche Riunite S.p.a.

Universta' Degli Studi Di Siena

7. 1 out of 832,680

Other

patents

where one patent can have more than one assignee

Years Active: 2008-2023

Loading Chart...

Loading Chart...

Loading Chart...

13 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11814366 - Antiviral compounds and use thereof (2023-11-14),

2. 11000512 - Use of DDX3 inhibitors as antiproliferative agents (2021-05-11),

3. 10941121 - Human helicase DDX3 inhibitors as therapeutic agents (2021-03-09),

4. 10093642 - Multitarget hedgehog pathway inhibitors and uses thereof (2018-10-09),

5. 10071975 - Macrocyclic amidinourea derivatives, methods of preparation and uses thereof as chitinase inhibitors (2018-09-11),

6. 8895600 - Non peptidic 14-3-3 inhibitors and the use thereof (2014-11-25),

7. 8685953 - Linear and cyclic guanidine derivatives, method of preparation and uses thereof (2014-04-01),

8. 8466164 - 4-substituted derivatives of pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine and uses thereof (2013-06-18),

9. 8304410 - Pyrrole compounds as inhibitors of mycobacteria, synthesis thereof and intermediates thereto (2012-11-06),

10. 8012970 - Derivatives of 1-{[1,5-bis(4-chlorophenyl)-2-methyl-1H-pyrrol-3-yl]methyl}-4-methylpiperazine, synthesis process and uses thereof (2011-09-06),

11. 7910581 - Derivatives of 1-{[1,5-bis(4-chlorophenyl)-2-methyl-1H-pyrrol-3-yl] methyl}-4-methylpiperazine, synthesis process and uses thereof (2011-03-22),

12. 7589086 - Substituted pyrazolo[3,4-D]pyrimidines as anti-tumor agents (2009-09-15),

13. 7368605 - Variously substituted derivatives of guanidine, and their use as medicines with anti-diabetes and/or anti-obesity activity (2008-05-06),

Title: Maurizio Botta: Innovator in Antiviral Compounds

Introduction

Maurizio Botta is a prominent inventor based in Siena, Italy. He has made significant contributions to the field of medicinal chemistry, particularly in the development of antiviral agents. With a total of 13 patents to his name, Botta's work has the potential to impact the treatment of various viral diseases.

Latest Patents

Among his latest patents, one notable invention is focused on antiviral compounds and their use as broad-spectrum antiviral agents. This invention relates to compounds of formula (I) and their application as medicaments, particularly in treating diseases caused by enveloped viruses. Another significant patent involves the use of DDX3 inhibitors as antiproliferative agents. This invention refers to compounds of formula I or II that exhibit DDX3 inhibitory activity, along with their pharmaceutical compositions and applications as antihyperproliferative agents.

Career Highlights

Maurizio Botta has worked with esteemed institutions such as the University of Siena and the University Hospital of Siena. His research has been pivotal in advancing the understanding and treatment of viral infections. His innovative approach to medicinal chemistry has garnered attention in the scientific community.

Collaborations

Throughout his career, Botta has collaborated with notable colleagues, including Fabrizio Manetti and Annalaura Brai. These partnerships have contributed to the success of his research and the development of his patented inventions.

Conclusion

Maurizio Botta's contributions to antiviral research and medicinal chemistry highlight his role as a leading inventor in the field. His innovative patents and collaborations reflect his commitment to advancing healthcare solutions.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com

Loading…